148 related articles for article (PubMed ID: 36657742)
1. Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis.
Marino A; Marelli L; Nucci P; Caporali R; Miserocchi E
Ocul Immunol Inflamm; 2023 Dec; 31(10):1997-2000. PubMed ID: 36657742
[TBL] [Abstract][Full Text] [Related]
2. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
3. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report.
Adán A; Moll-Udina A; Ramirez J; Llorenç V
Ocul Immunol Inflamm; 2021 Jan; 29(1):6-8. PubMed ID: 31589540
[No Abstract] [Full Text] [Related]
5. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.
Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G
J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis.
Quesada-Masachs E; Caballero CM
J Rheumatol; 2017 Feb; 44(2):260-261. PubMed ID: 28148759
[No Abstract] [Full Text] [Related]
9. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
10. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
Tappeiner C; Heinz C; Ganser G; Heiligenhaus A
J Rheumatol; 2012 Jun; 39(6):1294-5. PubMed ID: 22661419
[No Abstract] [Full Text] [Related]
11. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis.
Maleki A; Manhapra A; Asgari S; Chang PY; Foster CS; Anesi SD
Ocul Immunol Inflamm; 2021 Jan; 29(1):14-20. PubMed ID: 33021415
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab treatment for refractory uveitis-related cystoid macular edema.
Adán A; Mesquida M; Llorenç V; Espinosa G; Molins B; Hernández MV; Pelegrín L
Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2627-32. PubMed ID: 23893042
[TBL] [Abstract][Full Text] [Related]
14. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
[No Abstract] [Full Text] [Related]
16. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
Trials; 2014 Jan; 15():14. PubMed ID: 24405833
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.
García-De-Vicuña C; Díaz-Llopis M; Salom D; Bou R; Díaz-Cascajosa J; Cordero-Coma M; Ortega G; Ortego-Centeno N; Suarez-De-Figueroa M; Cruz-Martínez J; Fonollosa A; Blanco R; García-Aparicio ÁM; Benítez-Del-Castillo JM; Antón J
Mediators Inflamm; 2013; 2013():560632. PubMed ID: 24489444
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
